Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02276677 · ClinicalTrials.gov registry record · Early Phase 1

Oxytocin Effects on Food Motivation Pathways

A Early Phase 1 study of Overweight and Obesity, sponsored by Massachusetts General Hospital.

Completed
Registry status
Early Phase 1
Development phase
10
Enrollment target
1
Study location

NCT02276677: Completed Early Phase 1 study of Overweight and Obesity, sponsored by Massachusetts General Hospital.

NCT02276677 is a Early Phase 1 study of Overweight and Obesity that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants, below the 228-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02276677, a Early Phase 1 study of Overweight and Obesity, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Early Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Oxytocin is a peptide hormone produced in the brain that regulates food intake. However, the mechanisms for this effect in humans is not yet clear. In this study, the investigators will therefore examine the effect of a single dose of intranasal oxytocin (compared to placebo) on levels of appetite-regulating hormones and functional magnetic resonance imaging activation of areas of the brain involved in food motivation.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Oxytocin

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2014-10
Est. Completion 2015-05
Phase Early Phase 1
Massachusetts General Hospital

2,032 total trials

What the finished NCT02276677 record still lists

NCT02276677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 228-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Overweight and Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02276677 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02276677 about?

NCT02276677 is a clinical study titled "Oxytocin Effects on Food Motivation Pathways". Oxytocin is a peptide hormone produced in the brain that regulates food intake. However, the mechanisms for this effect in humans is not yet clear. In this study, the investigators will therefore examine the effect of a single dose of intranasal oxytocin (compared to placebo) on levels of appetite-...

What is the current status of trial NCT02276677?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2014-10. Estimated completion is 2015-05.

What conditions does trial NCT02276677 study?

This clinical trial studies the following conditions: Overweight and Obesity.

What interventions are being tested in trial NCT02276677?

The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).

Who is sponsoring clinical trial NCT02276677?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02276677 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Overweight and Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02276677's enrollment target sits among peer trials

10 113th of 115 higher than 3 of 115 other Overweight and Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Overweight and Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02276677, the US trial registry maintained by the National Library of Medicine. NCT02276677 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.